SPRUCE BIOSCIENCES, INC. (SPRB) Form 8-K — Nov 9, 2026
Spruce Biosciences reported a Q3 2026 net loss of $24.0 million ($8.51 per share), roughly triple the $8.2 million loss a year earlier, driven by R&D spending that jumped to $18.1 million from $5.0 million as it advances TA-ERT toward an FDA BLA submission in December 2026. Cash stood at $87.7 million, up from $48.9 million at year-end 2025, which the company says funds operations into the second half of 2027. Spruce amended its Avenue loan to increase Tranche 2 availability to $15 million and extend the interest-only period through March 31, 2027.
Key figures
- Revenue
- 0
- Total Assets
- 91948000
- Cash Position
- 87691000
- Shares Outstanding
- 2874013
- Cash runway
- into the second half of 2027
- Eap funding
- $5.5 million from Cure Sanfilippo Foundation and National MPS Society
- Eap enrollment
- approximately 10 participants
- Q3 2026 net loss
- $24.0 million vs $8.2 million in Q3 2025
- Q3 2026 gna expense
- $5.8 million vs $3.2 million in Q3 2025
- Q3 2026 rnd expense
- $18.1 million vs $5.0 million in Q3 2025
- Avenue tranche2 capacity
- $15.0 million (draw window Jan 1 – Mar 31, 2027)
- Nine month net loss 2026
- $52.5 million vs $24.3 million prior year
- Adrenyx convertible notes
- up to $10.0 million ($5.0 million issued at initial closing)
- Adrenyx private placement
- up to $50 million inclusive of note funding
- Transform study enrollment
- approximately 14 participants
AI analysis
Red flags5 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.